Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
CC transcript
|
|
BIOMIMETIC THERAPEUTICS, INC. (BMTI)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 03/06/2013 |
8-K
| Quarterly results |
| 02/26/2013 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 02/12/2013 |
8-K
| Other Events |
| 01/14/2013 |
8-K
| Other Events |
| 01/07/2013 |
8-K
| Other Events |
| 01/03/2013 |
8-K
| Other Events, Financial Statements and Exhibits |
| 11/06/2012 |
8-K
| Quarterly results|
Docs:
|
"BioMimetic Therapeutics, Inc. Reports Third Quarter 2012 Financial Results Franklin, Tenn. – November 5, 2012 – BioMimetic Therapeutics, Inc . today reported its corporate highlights and financial results as of and for the three and nine months ended September 30, 2012. For the three months ended September 30, 2012, the Company reported a net loss of $4.6 million, or $0.16 per diluted share, compared to a net loss of $7.1 million, or $0.25 per diluted share, for the same period in 2011. For the nine months ended September 30, 2012, the Company reported a net loss of $17.1 million, or $0.61 per diluted share, compared to a net loss of $23.3 million, or $0.83 per diluted share, for the same period in 2011. The Company ended the quarter with $44.3 million of cash, cash equivalents and investm..." |
|
| 09/18/2012 |
8-K
| Other Events |
| 07/09/2012 |
8-K
| Form 8-K - Current report |
| 06/21/2012 |
8-K
| Other Events, Financial Statements and Exhibits|
Docs:
|
"Timothy Daniels, MD Presents Results from Augment™ Injectable Bone Graft Clinical Trial Franklin, Tenn. – June 21, 2012 - Dr. Timothy Daniels, associate professor of orthopedic surgery at the University of Toronto and St. Michaels Hospital and lead investigator, presented today the results of a Canadian registration study comparing Augment™ Injectable Bone Graft to autograft in foot and ankle fusion surgery. AIBG is an injectable bone graft developed by BioMimetic Therapeutics, Inc. . The presentation took place on Thursday, June 21, 2012, at the American Orthopaedic Foot and Ankle Society annual meeting. As presented by Dr. Daniels, the trial met its primary endpoint of non-inferiority of AIBG to autograft as assessed by CT scan at six months. Dr. Daniels reported that assessm...",
"Slide Presentation" |
|
| 06/12/2012 |
8-K
| Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Submission of Matters to a Vot... |
| 05/10/2012 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits|
Docs:
|
"BioMimetic Therapeutics, Inc. Reports First Quarter 2012 Earnings Results Franklin, Tenn. – May 9, 2012 – BioMimetic Therapeutics , Inc. today reported its corporate highlights and financial results as of and for the three months ended March 31, 2012. For the three months ended March 31, 2012, the Company reported a net loss of $6.1 million, or $0.22 per diluted share, compared to a net loss of $8.0 million, or $0.28 per diluted share, for the same period in 2011. The Company ended the quarter with $54.5 million of cash and cash equivalents and investments. Corporate Development Highlights The following were some of the key Company highlights during the first quarter of 2012: · In January 2012, the Company announced receipt of a comprehensive post-panel response letter from the FDA ..." |
|
| 04/13/2012 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/14/2012 |
8-K
| Form 8-K - Current report |
| 03/05/2012 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/27/2012 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
| 01/20/2012 |
8-K
| Other Events |
| 01/03/2012 |
8-K
| Other Events, Financial Statements and Exhibits |
| 11/08/2011 |
8-K
| Form 8-K - Current report |
| 10/19/2011 |
8-K
| Other Events, Financial Statements and Exhibits |
| 08/05/2011 |
8-K
| Form 8-K - Current report |
| 07/01/2011 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
| 06/27/2011 |
8-K
| Regulation FD Disclosure |
| 06/15/2011 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Amendments to the Registrant's Code of Ethics, or W... |
| 06/10/2011 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 05/13/2011 |
8-K
| Form 8-K - Current report |
| 05/09/2011 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits|
Docs:
|
"BioMimetic Therapeutics, Inc. Reports First Quarter 2011 Earnings Results Company Initiates Patient Enrollment in Augment™ Injectable Bone Graft North American Pivotal Trial Franklin, Tenn. – May 9, 2011 – BioMimetic Therapeutics, Inc. , a biotechnology company specializing in the development and commercialization of innovative bioactive products to promote the healing of musculoskeletal injuries and diseases, today reported its financial results as of and for the three months ended March 31, 2011. For the three months ended March 31, 2011, the Company reported a net loss of $8.0 million, or $0.28 per diluted share, compared to a net loss of $8.5 million, or $0.39 per diluted share, for the same period in 2010. The Company ended the quarter with $83.7 million of cash and cash equival..." |
|
| 04/14/2011 |
8-K
| Form 8-K - Current report |
| 03/10/2011 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits|
Docs:
|
"BioMimetic Therapeutics, Inc. Reports 2010 Fourth Quarter and Year End Earnings Results Franklin, Tenn. – March 10, 2011 – BioMimetic Therapeutics, Inc. , a biotechnology company specializing in the development and commercialization of innovative bioactive products to promote the healing of musculoskeletal injuries and diseases, today reported its financial results as of and for the three and twelve months ended December 31, 2010. For the three months ended December 31, 2010, the Company reported a net loss of $10.0 million, or $0.36 per diluted share, compared to a net income of $1.1 million, or $0.05 per diluted share, for the same period in 2009. For the twelve months ended December 31, 2010, the Company reported a net loss of $33.9 million, or $1.38 per diluted share, compared to a net..." |
|
| 02/23/2011 |
8-K
| Form 8-K - Current report |
| 02/01/2011 |
8-K
| Form 8-K - Current report |
| 12/20/2010 |
8-K
| Form 8-K - Current report |
| 12/08/2010 |
8-K
| Other Events, Financial Statements and Exhibits |
| 11/04/2010 |
8-K
| Other Events, Financial Statements and Exhibits |
|
|
|